Innoviva swings to Q3 net loss of $73.89 million
INVA•Innoviva reported a third-quarter 2026 net loss of $73.9 million, primarily due to lower investment fair values. Revenue fell to $106.1 million, while operating income rose 22% to $42.2 million.
1. Quarterly results
Innoviva swung to a third-quarter 2026 net loss of $73.9 million, primarily due to lower investment fair values. Revenue fell year over year to $106.1 million, while income from operations climbed 22% to $42.2 million.
2. Buybacks and product
Innoviva repurchased $26.3 million of shares during the quarter under its $125 million buyback program. NUZOLVENCE, a single-dose oral antibiotic for uncomplicated urogenital gonorrhea, is now commercially available in the U.S.
